Vantage logo

Novo goes small with big Dicerna deal

Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.

Vantage logo

Storm hopes to rain on Accent’s parade

Epigenetics has so far failed to live up to the hype. But one UK player, Storm Therapeutics, still hopes to make a mark in a new field, RNA therapeutics.